Clinical Trial Update: Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Leuprolide Acetate Depot 22.5 mg in prostate cancer has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leuprolide Acetate Depot 22.5 mg (leuprolide acetate)

Snippet

Sponsor: GP-Pharm | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-01-18